Research

Hormonal

Tirzepatide improves hepatic steatosis and renal outcomes in patients with type 2 diabetes, independent of or additive to weight loss.

Tirzepatide not only helps with blood sugar and weight but also significantly reduces liver fat and protects kidney function in people with type 2 diabetes. This makes it a valuable option for those at risk of liver or kidney complications.

GoodSupportsHIGH confidence
The absolute difference in liver fat content [LFC] was − 4.7% (95% CI from − 6.7 to − 2.7), with a relative decrease in LFC from baseline of − 35.9% and − 28.4% for the two individual dosages (p < 0.0005)... The composite renal outcome (ESRD, eGFR decline > 40%, renal death, new onset of macroalbuminuria) strongly favored tirzepatide (HR 0.58, 95% CI from 0.43 to 0.80, p = 0.0008)
Stefano Ciardullo et al. · Acta Diabetologica · 2024

Why this rating

Based on post-hoc analyses of phase 3 trials (SURPASS-3, SURPASS-4).

Source

GLP1-GIP receptor co-agonists: a promising evolution in the treatment of type 2 diabetes

Stefano Ciardullo et al. · Acta Diabetologica · 2024

DOI 10.1007/s00592-024-02300-6

narrative_reviewCited 12×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →